ArticleJournal of assisted reproduction and genetics2025
Overexpressed miR-135b in the ovaries of PCOS promotes granulosa cell proliferation by inhibiting Hippo signaling pathway.
Article in Journal of assisted reproduction and genetics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPolycystic ovary syndrome (PCOS) is a multifactorial endocrine disorder, characterized by ovarian structural abnormalities that lead to ovulatory dysfunction. The Hippo signaling pathway is crucial in regulating ovarian enlargement and cortical thickening, which are hallmarks of PCOS, although the regulatory mechanisms remain unclear.
methodsWe assessed the expression of miR-135b and its target gene LATS2 (large tumor suppressor 2) in granulosa cells from both PCOS and normal ovaries using quantitative PCR. Dual-luciferase assays confirmed their direct interaction. The expression and localization of YAP (yes-associated protein), a key effector of the Hippo pathway, were examined through immunofluorescence in granulosa cells (GCs) from both groups. Additionally, the impact of miR-135b overexpression or inhibition on Hippo pathway genes was investigated in the KGN granulosa cell line, with changes in cell proliferation and apoptosis analyzed by cell proliferation assay and flow cytometry.
resultsMiR-135b was significantly upregulated (9.15-fold) in PCOS granulosa cells and targeted LATS2, a critical Hippo pathway regulator. Dual-luciferase assays confirmed the miR-135b binding site in the 3'-UTR of LATS2. Mechanistically, high miR-135b expression reduced LATS2 levels, impairing YAP phosphorylation, promoting nuclear translocation of unphosphorylated YAP, and driving excessive granulosa cell proliferation.
conclusionOur findings suggest that miR-135b overexpression in PCOS ovaries contributes to abnormal granulosa cell proliferation by inhibiting the Hippo pathway. This study enhances our understanding of ovarian abnormalities in PCOS and identifies miR-135b as a potential biomarker and therapeutic target for the disorder.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.